Disclosing Conflicts of Interest in Clinical Research: Views of Institutional Review Boards,Conflict of Interest Committees,and Investigators

Angell M. , “Is Academic Medicine for Sale?” New England Journal of Medicine 342 (2000): 1516–1518; Bodenheimer T. , “Uneasy Alliance – Clinical Investigators and the Pharmaceutical Industry,” New England Journal of Medicine 342 (2000): 1539–1544; Korenman S. G. , “Conflicts of Interest and Commercialization of Research,” Academic Medicine 68, no. 9 (suppl) (1993): S18–S22; Shalala D. , “Protecting Research Subjects – What Must Be Done,” New England Journal of Medicine 343 (2000): 808–810.

Department of Health and Human Services, “Financial Relationships and Interests in Research Involving Human Subjects: Guidance for Human Subject Protection,” Federal Register 69 (2004): 26393–26397.

Weinfurt K. P. Dinan M. A. Allsbrook J. S. , “Policies of Academic Medical Centers for Disclosing Conflicts of Interest to Potential Research Participants,” Academic Medicine 81 (2006): 113–118.

45 C.F.R. § 46 (2005); 21 C.F.R. § 50 (2005); 21 C.F.R. § 56 (2005).

Krueger R. A. , Focus Groups, 2nd edition (Thousand Oaks, CA: Sage Publications, 1994).

Faden R. R. and Beauchamp T. L. , A History and Theory of Informed Consent (New York: Oxford University Press, 1986).

See Weinfurt , supra note 3.

Cain D. M. Loewenstein G. , and Moore D. A. , “The Dirt on Coming Clean: Perverse Effects of Disclosing Conflicts of Interest,” Journal of Legal Studies 34 (2005): 1–25.

Boyd E. A. Cho M. K. , and Bero L. A. , “Financial Conflict-of-Interest Policies in Clinical Research: Issues for Clinical Investigators,” Academic Medicine 78 (2003): 769–774.

Id.; Resnik D. B. , “Disclosing Conflicts of Interest to Research Subjects: An Ethical and Legal Analysis,” Accountability in Research 11 (2004): 141–159; Schneider C. E. , “Reaching Disclosure,” Hastings Center Report 35 (2005): 12–13.